RSNA 2012 Press Releases
Monday, November 26, 2012
MR Imaging Predicts Overall Survival of Patients with Recurrent Glioblastoma Early-on in Treatment Regimen with Bevacizumab
Results of an ACRIN study demonstrate that changes in tumor enhancement on post-gadolinium (Gd) T1-weighted magnetic resonance imaging (MRI) are highly predictive of which patients with recurrent glioblastoma (GBM) brain tumors will benefit from second-line therapy that includes the antiangiogenic drug bevacizumab.
Read the full release.
An Open Source and Automated Lesion Tracking Tool Significantly Increases Efficiency of Quantitative Image Interpretation
A pilot study evaluating radiologists’ use of the electronic Physician Annotation Device (ePAD), a research project of the ACRIN’s Biomedical Informatics Committee, demonstrates a 23 percent increase in reader efficiency.
Read the full release.
More at RSNA 2012Review the ECOG-ACRIN scientific presentations at the RSNA 2012 Annual Meeting as you prepare your meeting schedule.
Visit the demonstration "Tools for quantitative imaging assessment of treatment response in the American College of Radiology Imaging Network" featured as part of the Quantitative Imaging Reading Room Showcase in the Lakeside Learning Center (LL-QRR3003) to see the ePAD in action.
Stop by the ACR Booth (South Building #4429) for an update about the ongoing clinical trials and new trials in development. Learn how you can participate in the cardiovascular imaging trial RESCUE and other trials recruiting new sites. Plus, investigate all the new educational opportunities and services offered by the ACR.
| Wendie A Berg, MD, PhD
||What if US Was the Primary Screening Test for Breast Cancer? Analysis from ACRIN 6666
|SSA01 | Arie Crown Theater|
| Habib Rahbar, MD
||Contralateral Prophylactic Mastectomy in the ACRIN 6667 Trial: Impact of Breast MR Assessments and Patient Characteristics
||Wednesday 03:00-04:00 PM
||SSM02 | E451A|
|Jerrold Lee Boxerman, MD, PhD
||Early Post-Bevacizumab Progression Status by MRI Predicts Overall Survival in Recurrent Glioblastoma: Results from the ACRIN 6677/RTOG 0625 Central Reader Study
|VSNR21 | E451B|
| Daniel L Rubin, MD
||Evaluation of Automated Lesion Tracking Tool to Improve Radiologist Efficiency in RECIST Assessments
|SSC08 | S402AB|
|Daniel L Rubin, MD
||Tools for quantitative imaging assessment of treatment response in ACRIN
Demonstration runs through Thurs.
|Meet the Experts Schedule: